Anti–programmed cell death–1 (PD-1) antibody blockade has revolutionized cancer treatment by enhancing immune responses against tumors. However, anti–PD-1 treatment can also induce immune-related adverse events by promoting autoreactive immune responses. In this study, Yasuda et al. investigated the immune cell type responsible for promoting destructive thyroiditis, a common adverse event observed in patients treated with anti–PD-1 antibody. The authors found that CD4+ T cells are required for the onset of destructive thyroiditis in a mouse model, which was supported by analysis of circulating CD4+ T cells isolated from patients. These results suggest that CD4+ T cells may mediate destructive thyroiditis in patients with cancer after anti–PD-1 treatment.
Immune-related adverse events induced by anti–programmed cell death–1 antibodies (PD-1-Ab), including destructive thyroiditis (thyroid-irAE), are thought to be caused by activated T cells. However, the T cell subsets tha
Interrupting RNA activity can improve cancer survival newzealandstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newzealandstar.com Daily Mail and Mail on Sunday newspapers.
Interrupting RNA activity can improve survival chances in pancreatic cancer patients ANI | Updated: Apr 24, 2021 17:15 IST
Nagoya [Japan], April 24 (ANI): During a recent study, researchers uncovered a molecular pathway that enhances chemotherapy resistance in some pancreatic cancer patients. A patient s response to therapy and their overall survival chance can be increased by targeting an RNA to interrupt its activity.
The study led by Nagoya University researchers and colleagues in Japan was published in the journal Cancer Research. Pancreatic cancer is one of the most aggressive human malignancies, with an overall med ian survival that is less than five months, says cancer biologist Yutaka Kondo of Nagoya University Graduate School of Medicine. This poor prognosis is partially due to a lack of potent therapeutic strategies against pancreatic cancer, so more effective treatments are urgently needed.
E-Mail
IMAGE: Kondo and his team found TUG1 overexpression in some pancreatic cancer patients leads to increased release of an enzyme (DPD), which breaks down the chemotherapeutic, 5-FU, into a compound that. view more
Credit: Yutaka Kondo
Nagoya University researchers and colleagues in Japan have uncovered a molecular pathway that enhances chemotherapy resistance in some pancreatic cancer patients. Targeting an RNA to interrupt its activity could improve patient response to therapy and increase their overall survival. Pancreatic cancer is one of the most aggressive human malignancies, with an overall median survival that is less than five months, says cancer biologist Yutaka Kondo of Nagoya University Graduate School of Medicine. This poor prognosis is partially due to a lack of potent therapeutic strategies against pancreatic cancer, so more effective treatments are urgently needed.
Study focuses on improving survival in pancreatic cancer aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.